TG Therapeutics Raises Revenue Forecast on Strong BRIUMVI Sales

TG Therapeutics has reported Q2 revenue of $141.1mln, driven by strong sales of BRIUMVI, which contributed $138.8mln, a 91% YoY increase. The company has raised its full-year revenue guidance for BRIUMVI and has expanded its commercialization internationally. TG Therapeutics is pursuing further development of BRIUMVI, including a subcutaneous formulation and consolidated dosing regimen, to enhance its market position.

TG Therapeutics, Inc. (NASDAQ: TGTX) reported robust financial results for the second quarter of 2025, with total revenue reaching $141.1 million. The company's flagship product, BRIUMVI, contributed significantly to this growth, with U.S. net revenue of $138.8 million, representing a 91% year-over-year (YoY) increase [1].

The strong performance of BRIUMVI is driven by its unique anti-CD20 therapy for adults with relapsing multiple sclerosis (MS). The company has raised its full-year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million, reflecting the product's growing popularity and market potential [1]. Additionally, TG Therapeutics has expanded its commercialization efforts internationally, with BRIUMVI now approved in the European Union, United Kingdom, Switzerland, and Australia, further bolstering its global reach [1].

In addition to its revenue growth, TG Therapeutics is continuing to innovate and develop new formulations of BRIUMVI. The company is currently studying a subcutaneous formulation and a consolidated day one and day fifteen IV dosing regimen, which could enhance the product's market position and patient experience [1].

The company's R&D expenses for the quarter increased to $31.8 million, primarily due to costs associated with the development of the ublituximab subcutaneous formulation [1]. Despite these expenses, TG Therapeutics reported net income of $28.2 million for the three months ended June 30, 2025, up from $6.9 million for the same period in 2024 [1]. The company's cash position as of June 30, 2025, was $278.9 million, providing a solid financial foundation for future growth [1].

TG Therapeutics will host a conference call today, August 4, 2025, at 8:30 AM ET to discuss its Q2 financial results and provide further updates on its pipeline and commercialization efforts [1].

References:
[1] https://www.biospace.com/press-releases/tg-therapeutics-reports-second-quarter-2025-financial-results-and-raises-briumvi-revenue-guidance